Nutrition, Metabolism & Cardiovascular Diseases
Volume 20, Issue 8 , Pages 553-557 , October 2010

HDL and LDL as therapeutic targets for cardiovascular disease prevention: The possible role of niacin

  • A.G. Olsson

      Affiliations

    • Corresponding Author InformationTel.: +46 8 262056; fax: +46 8 262015.

Received 26 May 2010 ,Revised 12 July 2010 ,Accepted 14 July 2010.

References 

  1. CDP Research Group . Clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360–381
  2. Canner P, Berge K, Wenger N, Stamler J, Friedman L, Prineas R, et al. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245–1255
  3. Carlson L, Rosenhamer G. Reduction of mortality in the Stockholm ischaemic heart disease secondary prevention study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand. 1988;223(5):405–418
  4. Brown BG, Zhao X-Q, Chait A, Fisher LD, Cheung MC, Morse JS, et al. Simvastatin and niacin, Antioxidant Vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345(22):1583–1592
  5. Taylor AJ, Villines TC, Stanek EJ, Devine PJ, Griffen L, Miller M, et al. Extended-Release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med. 2009;361(22):2113–2122
  6. Lee JMS, Robson MD, Yu L-M, Shirodaria CC, Cunnington C, Kylintireas I, et al. Effects of high-dose modified-release nicotinic acid on atherosclerosis and Vascular Function: a randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol. 2009;54(19):1787–1794
  7. Blumenthal RS, Michos ED. The HALTS trial – Halting atherosclerosis or Halted Too early?. N Engl J Med. 2009;361(22):2178–2180
  8. Kastelein JJP, Bots ML. Statin therapy with ezetimibe or niacin in high-risk patients. N Engl J Med. 2009;361(22):2180–2183
  9. Carlson L. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med. 2005;258(2):94–114
  10. Crouse J, Raichlen J, Riley W, Evans G, Palmer M, O’Leary D, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA. 2007;297(12):1344–1353
  11. Rossebo AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359(13):1343–1356
  12. Finn AV, Kolodgie FD, Virmani R. Correlation between carotid intimal/medial thickness and atherosclerosis: a point of view from pathology. Arterioscler Thromb Vasc Biol. February 1, 2010;30(2):177–181
  13. Coronary Drug Project report on clofibrate and niacin. Atherosclerosis. 1978;30(3):239–240
  14. Benyó Z, Gille A, Kero J, Csiky M, Suchánková MC, Nusing RM, et al. GPR109A (PUMA-G/HM74A) mediates nicotinic acidinduced flushing. J Clin Invest. 2005;115(12):3634–3640
  15. Cheng K, Wu T-J, Wu KK, Sturino C, Metters K, Gottesdiener K, et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. 2006 April 25, 2006;103(17):6682–7.
  16. Morrow JD, Awad JA, Oates JA, Roberts LJ. Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans. J Invest Dermatol. 1992 May;98(5):812–815
  17. Paolini J, Bays H, Ballantyne C, Davidson M, Pasternak R, Maccubbin D, et al. Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors. Cardiol Clin. 2008;26(4):547–560
  18. Maccubbin D, Bays HE, Olsson AG, Elinoff V, Elis A, Mitchel Y, et al. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract. 2008;62(12):1959–1970
  19. Norquist JM, Watson DJ, Yu Q, Paolini JF, McQuarrie K, Santanello NC. Validation of a questionnaire to assess niacin-induced cutaneous flushing. Curr Med Res Opin. 2007;23(7):1549–1560
  20. Kaijser L, Eklund B, Olsson A, Carlson L. Dissociation of the effects of nicotinic acid on vasodilatation and lipolysis by a prostaglandin synthesis inhibitor, indomethacin, in man. Med Biol. 1979;57(2):114–117
  21. HPS2-THRIVE: Treatment of High density lipoprotein to Reduce the Incidence of Vascular Events [database on the Internet]. 2008.
  22. Cannon CP, Giugliano RP, Blazing MA, Harrington RA, Peterson JL, Sisk CM, et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: vytorin Efficacy International Trial): Comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J. 2008;156(5):826–832
  23. Califf RM, Lokhnygina Y, Cannon CP, Stepanavage ME, McCabe CH, Musliner TA, et al. An update on the improved reduction of outcomes: vytorin efficacy International Trial (IMPROVE-IT) design. Am Heart J. 2010;159(5):705–709

PII: S0939-4753(10)00170-5

doi: 10.1016/j.numecd.2010.07.003

Nutrition, Metabolism & Cardiovascular Diseases
Volume 20, Issue 8 , Pages 553-557 , October 2010

Article Tools

* Image Usage & Resolution